http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 16:39:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NORTHWEST+BIOTHERAPEUTIC++For%3A+Mar+31/26506799.html si-local-file:///var/storage/secattach/20260515/26506799.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NORTHWEST+BIOTHERAPEUTIC++For%3A+Mar+31/26506799.html Fri, 15 May 2026 16:39:00 -0400 NWBO O.05138324 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NORTHWEST+BIOTHERAPEUTIC++For%3A+Mar+31/26506799.html si-local-file:///var/storage/secattach/20260515/26506799.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NORTHWEST+BIOTHERAPEUTIC++For%3A+Mar+31/26506799.html Fri, 15 May 2026 16:39:00 -0400 NWBO O.05138324 http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Press+Releases/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cHBGEHVTYTLZF4FeftHMKdq-p-IOGwmXqwchrFI4Et8vfLVfTNiqH1eAOrforh67-fagaugyo5_2a8um0LsOiTEEABz_SdRWCqmndWleP6O-dkyfpZHJV2Kcv5CfilevOJQEkBfnAier5kwLPaZTdjL2L-_VqrqdXMD8zAAyv7-aDZKXPHuZUlfvnpi19KEnUf1DfEH_CH9DYe1betq4l__GVMszy7Qtp7mNZboHWQ9fO8AyodTf_0HzKX1ubpEjoErzSip7rHfsdOSj81_NaKnZmQstrYRojAfAZd6kOxeVL_TfwzGEvMlWpdKKtyH4" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: http://www.streetinsider.com/Globe+Newswire/CNS+Drug+Delivery+Breakthroughs+Unlock+Significant+Biotech+Market+Opportunities/26465700.html Mon, 11 May 2026 08:30:00 -0400 A.35552990 BIIB CYDY MRNA NWBO O.00070139 O.00074346 O.01670430 O.02282972 O.05138324 O.39449410 OTLC